DV
Dividend Vision

ELVN — Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. (ELVN)

Total return is -2.0% over the past 6.4 years, 245.3 points behind SPY at 243.3%. Its deepest 1-year drawdown was 36.8%.

This is a single-stock equity holding in Enliven Therapeutics, Inc., a therapeutics company, rather than a diversified ETF. The holding generates no dividend distributions and carries no disclosed expense ratio information. This security appeals primarily to growth-oriented investors seeking exposure to the therapeutics sector rather than income-focused dividend investors.

ELVN key facts

Asset type
Stock
Asset class
Equity
Inception date
03/12/2020
Distribution frequency
None
Last close
$58.82
Market cap
$4,309,786,112
Average volume
350290.0
Beta
0.241
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.65